isavuconazole及其潜在的严重侵袭性真菌感染的治疗。

文章的细节

引用

复制到剪贴板

Falci博士,巴AC

isavuconazole及其潜在的严重侵袭性真菌感染的治疗。

感染药物抵抗。2013年10月22日,6:163 - 74。doi: 10.2147 / IDR.S51340。

PubMed ID

24187505 (在PubMed

]

文摘

三唑类抗真菌药物包括一些侵入性真菌疾病的一线药物治疗。Isavuconazole是一种新型广谱三唑代理。在这里,我们总结其特点和当前可用的抗真菌药物进行比较。Isavuconazole管理作为一个前药,水溶性。口服给药和静脉注射配方是可用的。静脉注射配方不含环糊精,伏立康唑是一种优势,考虑环糊精的潜在肾毒性。与其他唑类一样,isavuconazole需要负荷剂量。由于其半衰期延长,一种方案是可能的。考虑到isavuconazole股票氮杂四唑的作用机制与其他相同,抗力移转是一个重要的问题在课堂上。良好的耐受性和安全性配置文件,没有持续严重不良事件报告。 Significant interactions with drugs metabolized by cytochrome P450 are expected to occur, especially with substrates and inducers of the CYP3A4 enzyme. Isavuconazole has in vitro activity against most medically important fungi, including species of Candida, Aspergillus, and Cryptococcus. It has some activity against the agents of mucormycosis. Clinical data regarding isavuconazole remain limited because ongoing trials have not yet been completed or published. Isavuconazole has the potential to become first-line therapy for invasive aspergillosis. It also has the potential for use in the context of antifungal prophylaxis, salvage therapy, or in combination regimens. Results of clinical trials are ultimately expected in order to adequately position isavuconazole in the current antifungal armamentarium.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

Isavuconazole